Keyword: Arena Pharmaceuticals

Eisai's Belviq has long struggled to prove itself in obesity. With a recall underway after a cancer risk scare, Belviq's chances may be gone for good.

Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.

To partner or not to partner on a new drug launch? Of all the decisions emerging biopharma companies have to make, that's among the most important.

Arena has endured a rocky few years with obesity med Belviq. But now, the underperforming drug will be marketing partner Eisai's problem.